Hardman Johnston Global Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Hardman Johnston Global Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-165,610	Closed	-$14.5M	–	77
2024 Q1	$14.5M	Sell	165,610 -4,950	-3%	-$443K	0.5%	44
2023 Q4	$16.4M	Sell	170,560 -1,570	-0.9%	-$139K	0.53%	42
2023 Q3	$15.2M	Sell	172,130 -1,400	-0.8%	-$125K	0.51%	43
2023 Q2	$15M	Buy	173,530 +82,130	+90%	+$7.73M	0.49%	48
2023 Q1	$8.89M	Buy	+91,400	New	+$9.48M	0.29%	52

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Hardman Johnston Global Advisors's BMRN Position: Q2 2024 in Review

Hardman Johnston Global Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 165,610 shares — an estimated $14.5M sold.

Hardman Johnston Global Advisors first reported a position in BMRN in Q1 2023 and held it in 5 quarters. The position peaked at $16.4M in Q4 2023. 559 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

Hardman Johnston Global Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Hardman Johnston Global Advisors sold 165,610 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $14.5M.
Hardman Johnston Global Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2023 and held it in 5 quarters.
Hardman Johnston Global Advisors's BioMarin Pharmaceuticals position peaked at $16.4M in Q4 2023.
559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on Hardman Johnston Global Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.